Evaluation and Management of Multiple Healing Lower Leg Lesions in a 10-Year-Old
This child requires a thorough clinical examination to determine if the lesions represent juvenile localized scleroderma (JLS), and if suspected, should be referred immediately to a specialized pediatric rheumatology center for definitive diagnosis and treatment 1.
Initial Clinical Assessment
The key diagnostic priority is distinguishing between benign self-resolving conditions and JLS, which can cause permanent disfigurement and disability if untreated. Focus your examination on:
Skin Lesion Characteristics
- Activity markers: Look for violaceous borders, erythema, or warmth indicating active inflammation versus hyperpigmentation or atrophy suggesting inactive/healing lesions
- Texture: Assess for induration, skin thickening, or hardening (sclerosis) versus soft, normal texture
- Pattern: Linear distribution along limbs suggests linear scleroderma (the most common JLS subtype in children, mean onset 7.3 years) 1
- Depth: Determine if lesions are superficial or involve deeper tissues
Critical Extracutaneous Evaluation
Since JLS can affect more than skin, examine for:
- Joint involvement: Complete joint examination including range of motion, particularly if lesions cross joints 1
- Limb measurements: Document any limb length discrepancies or muscle atrophy
- Growth patterns: Linear lesions can cause growth arrest in affected limbs
Diagnostic Workup
When to Refer Urgently
Refer to pediatric rheumatology if you identify:
- Indurated or sclerotic plaques (even if healing)
- Linear lesions on extremities
- Any signs of joint contracture or limb asymmetry
- Skin thickening or texture changes
The guideline explicitly states that given JLS rarity (3.4 cases per million children annually), suspected cases require specialized assessment 1.
If JLS is Confirmed
MRI should be considered to assess musculoskeletal involvement, especially when lesions cross joints 1. This is crucial because subcutaneous involvement can cause significant morbidity even when skin appears to be healing.
Treatment Implications
If active JLS is diagnosed, treatment is time-sensitive:
- All patients with active, potentially disfiguring or disabling JLS should receive methotrexate 15 mg/m²/week (Level 1b evidence, Grade A recommendation) 1
- Systemic corticosteroids may be added during the active inflammatory phase 1
- Treatment should continue for at least 12 months after achieving clinical improvement 1
Alternative Diagnoses to Consider
If lesions are truly healing without intervention and examination shows no sclerosis:
- Idiopathic calcinosis cutis: Can present as multiple subcutaneous nodules on legs and may resolve spontaneously over 18 months with observation alone 2
- Post-traumatic lesions: Sports-related injuries in this age group are common 3
However, the "wait-and-see" approach is only appropriate when you've definitively ruled out JLS through expert evaluation, as delayed treatment of active JLS leads to permanent tissue damage and disability.
Critical Pitfall
The most dangerous error is assuming "healing" lesions are benign. JLS lesions can appear to improve superficially while deeper sclerosis progresses, causing irreversible joint contractures, limb length discrepancies, and functional impairment. The post-inflammatory hyperpigmentation phase of JLS can be mistaken for healing when active disease persists in deeper tissues 1.